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Abstract
Rationale:Goblet cell metaplasia accompanies common pulmonary
disorders that are prone to recurrent viral infections. Mechanisms
regulating both goblet cell metaplasia and susceptibility to viral
infection associated with chronic lung diseases are incompletely
understood.
Objectives:We sought to identify the role of the transcription factor
FOXA3 in regulation of goblet cell metaplasia and pulmonary
innate immunity.
Methods: FOXA3 was identified in airways from patients with
asthma and chronic obstructive pulmonary disease. We produced
transgenic mice conditionally expressing Foxa3 in airway epithelial
cells and developed human bronchial epithelial cells expressing
Foxa3. Foxa3-regulated genes were identified by immunostaining,
Western blotting, and RNA analysis. Direct binding of FOXA3 to
target genes was identified by chromatin immunoprecipitation
sequencing correlated with RNA sequencing.
Measurements and Main Results: FOXA3 was highly expressed
in airway goblet cells from patients with asthma and chronic
obstructive pulmonary disease. FOXA3 was induced by either IL-13
or rhinovirus. Foxa3 induced goblet cell metaplasia and enhanced
expression of a network of genes mediating mucus production.
Paradoxically, FOXA3 inhibited rhinovirus-induced IFN
production, IRF-3 phosphorylation, and IKKe expression and
inhibited viral clearance and expression of genes required for
antiviral defenses, including MDA5, RIG-I, TLR3, IRF7/9, and
nuclear factor-kB.
Conclusions: FOXA3 induces goblet cell metaplasia in response to
infection or Th2 stimulation. Suppression of IFN signaling by
FOXA3 provides a plausible mechanism that may serve to limit
ongoing Th1 inflammation during the resolution of acute viral
infection; however, inhibition of innate immunity by FOXA3 may
contribute to susceptibility to viral infections associated with chronic
lung disorders accompanied by chronic goblet cell metaplasia.
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Goblet cell metaplasia, hypersecretion of
mucus, and inflammation complicate
common acute and chronic pulmonary
disorders that contribute to morbidity and
mortality from lung diseases throughout the
world (reviewed in Reference 1). Mucous
metaplasia, as seen in asthma, cystic fibrosis
(CF), chronic obstructive pulmonary
disease (COPD), bronchiectasis, and other
(Received in original form June 28, 2013; accepted in final form December 13, 2013 )
*Current address: The Bill and Melinda Gates Foundation, 440 5th Avenue N, Seattle, WA 98102.
Supported by the NHLBI Lung Repair and Regeneration Consortium and NIH grants HL110964, HL095580, and HL108907 (J.A.W. and T.R.K.); NIH grant
AI088372 (C.L.K.); the Cystic Fibrosis Foundation Research Development Program and American Lung Association Senior Research Training Fellowship
and University of Cincinnati Postdoctoral Research Award (G.C.); and Medical Research Council Clinician Scientist Fellowship (H.M.H.).
Author Contributions: G.C., S.I., Y.X., and J.K. designed and performed experiments, analyzed results, and wrote the manuscript. A.P.S. provided RV1B and
RV16 rhinovirus, and S.H.R. provided primary human bronchial epithelial cells and acute asthma specimens. A.S. performed experiments, analyzed results,
and reviewed the manuscript. Y.M., H.M.H., and C.L.K. helped design experiments and reviewed the manuscript. J.A.W. and T.R.K. conceived strategies,
supervised the project, interpreted results, and wrote the manuscript.
Correspondence and requests for reprints should be addressed to Jeffrey A. Whitsett, M.D., Cincinnati Children’s Hospital Medical Center, Division of
Neonatology, Perinatal and Pulmonary Biology, 3333 Burnet Avenue, MLC7029, Cincinnati, OH 45229-3039. E-mail: jeffrey.whitsett@cchmc.org
This article has an online supplement, which is accessible from this issue’s table of contents at www.atsjournals.org
Am J Respir Crit Care Med Vol 189, Iss 3, pp 301–313, Feb 1, 2014
Copyright © 2014 by the American Thoracic Society
Originally Published in Press as DOI: 10.1164/rccm.201306-1181OC on January 6, 2014
Internet address: www.atsjournals.org
Chen, Korfhagen, Karp, et al.: FOXA3 Regulates Pulmonary Innate Immunity 301
chronic pulmonary disorders, is commonly
associated with recurrent viral and bacterial
infections that contribute to clinical
exacerbations and declines in pulmonary
function (2–4). Paradoxically, in spite of the
inflammation associated with chronic
respiratory disorders, these patients are
susceptible to both viral and bacterial
infections and often fail to fully clear
microbial pathogens from the airways.
Secondary infections are a common
occurrence during recovery from
pulmonary viral infections (5). The
mechanisms underlying the susceptibility
to recurrent infection associated with
chronic lung diseases are complex and
incompletely understood.
Goblet cell metaplasia and
hyperplasia are induced by various
inflammatory mediators, including Th2
cytokines after pulmonary aeroallergen,
viral, and toxicant exposure, and after
activation of epidermal growth factor
receptor and Notch signaling (6–9). At
the transcriptional level, airway goblet
cell metaplasia induced by Th2 cytokines
is mediated by SPDEF, the activation of
which requires STAT6 and the inhibition
of NKX2-1 and FOXA2 in airway
epithelial cells (10–12). SPDEF is
sufficient and necessary for goblet cell
metaplasia, and expression of SPDEF is
increased in airway epithelial cells of
patients with CF and in chronic smokers
(13). In transgenic mice, expression of
Spdef induces Foxa3 (also termed
HNF3g) in airway goblet cells (13).
Likewise, FOXA3 is increased after
aeroallergen exposure in mice but is not
required for goblet cell metaplasia in that
model (14). The role of FOXA3 in the
regulation of respiratory epithelial cell
mucous metaplasia and innate immune
responses is unknown.
Rhinoviruses (RVs) are the pathogen
most commonly associated with the
respiratory infections termed “the
common cold.” RV infections are
associated with respiratory tract infection
and inflammation that also frequently
complicate the clinical course of patients
with chronic lung diseases (2–4). RV
readily infects respiratory epithelial cells,
eliciting inflammation and antiviral
responses that are dependent on IFN
production and expression of IFN-
stimulated genes (ISGs). Production of
double-stranded RNAs during RV
replication leads to signaling through
endosomal TLR3 activating IRF3 (15)
and the production of IFNs and
intracellular RNA helicases RIG-I and
MDA-5 that are critical for viral
clearance (16, 17). RV induces
neutrophilic and lymphocytic
inflammation and enhances Muc5ac
expression in mouse lungs (18).
The present study was designed to
identify the role of FOXA3 in the regulation
of goblet cell metaplasia and innate
immunity in airway epithelial cells. FOXA3
was induced in airway epithelial cells after
exposure to RV in vivo and in vitro. FOXA3
was sufficient to cause goblet cell
metaplasia in transgenic mice and in
human bronchial epithelial cells (HBECs)
in vitro and inhibited IFN responses.
Although inhibitory effects of FOXA3 on
IFN signaling may serve to dampen
inflammatory responses during resolution
of acute infections, chronic expression of
FOXA3 associated with mucous metaplasia
may contribute to susceptibility to infection




Human samples were deidentified and
studies were performed in accordance with
institutional review board (IRB) approval at
Cincinnati Children’s Hospital (CCHMC
ID: 2012-2853). Samples from patients with
COPD were obtained from pathological
tissues provided by Dr. Andreas Gunther,
University of Giessen Lung Center, Giessen,
Germany in accordance with IRB approval.
HBECs and tissue from patients with
asthma were obtained under approved
protocols at the University of North
Carolina, Chapel Hill. HBECs were
produced under Biomedical IRB Protocol
#103-1396.
Mouse Models, Ovalbumin, House
Dust Mite, and RV1B Sensitization
Mouse strains included in this study were
C57/B6 Foxa32/2 mice and FVB/N
Scgb1a1-rtTA (line 2) bred to Otet7 -Foxa3-
IRES-EGFP mice. Ovalbumin, house dust
mite (HDM), and RV1B sensitization
protocols are provided in the online
supplement.
Immunohistochemistry, Alcian Blue
Staining, and Confocal Microscopy
Adult mouse lungs sections were
stained with Alcian blue and/or
immunohistochemical staining as
previously described (12, 13, 19). For
confocal microscopy, BEAS2B cells that
were stably transfected with lentiviral
constructs were dual stained with
antibodies for FOXA3 and MUC5AC (13)
(online supplement).
RV Culture, Infection, IFN-b, and
IL-13 Administration
Amplification of RV1B followed the
standard protocols as previously described
(18). Infection with RV and treatment of
primary HBECs with IFN-b or IL-13 were





assays were conducted as described
previously (24). BEAS2B-GFP and
BEAS2B-Foxa3 transfected cells
were fixed with 1% formaldehyde for
10 minutes at room temperature. Chromatin
was sonicated and immunoprecipitated
At a Glance Commentary
Scientific Knowledge on the Subject:
Mucous metaplasia in chronic
pulmonary disorders is commonly
associated with recurrent viral and
bacterial infections that contribute to
clinical exacerbations. Mechanisms
mediating goblet cell differentiation
and the increased susceptibility to
recurrent infections associated with
chronic lung diseases are incompletely
understood.
What This Study Adds to the Field:
FOXA3, a transcription factor
expressed in the goblet cells in the
airways of patients with asthma and
COPD, regulates a network of genes
mediating mucus production and
causes goblet cell differentiation.
FOXA3 also inhibits rhinovirus-
induced IFN production and viral
clearance by the lung. The suppression
of antiviral responses by FOXA3
provides a plausible mechanism
linking goblet cell metaplasia and
susceptibility to infection associated
with chronic pulmonary diseases.
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using a FOXA3 antibody (Santa Cruz
Biotechnology, Dallas, TX) overnight.
ChIP–polymerase chain reaction analysis
was conducted using real-time polymerase
chain reaction. ChIP-sequence (ChIP-Seq)
libraries were generated and sequenced
using standard Illumina protocols. Reads
(approximately 50 bp per fragment) were
mapped to the human genome (UCSC
hg19) using the Bowtie2 algorithm (39
trimmed 40 bp reads and three
mismatches). Only sequences that mapped
to a single genomic location were selected
(online supplement).
Statistics
Student t test (two-tailed, unpaired) and
nonparametric Mann-Whitney test (two-
tailed, unpaired) (Prism 6; Graphpad, La
Jolla, CA) were used for comparison of
statistical differences between two groups.
Nonpairing one-way analysis of variance
(Prism 6) was used for comparison of
statistical differences between three or more
groups; P values of less than 0.05 were
considered significant difference.
Results
FOXA3 Is Highly Expressed in Airway
Goblet Cells from Patients with
Asthma and COPD
Intense nuclear staining of FOXA3 was
detected in airway goblet cells in tissue
from patients with COPD and asthma.
FOXA3 staining was restricted to
epithelial cells and closely associated
with Alcian blue and SPDEF, both
characteristic of airway goblet cells.
FOXA3 was much less abundant in
airway epithelial cells in tissues from
healthy individuals (Figure 1). Th2
cytokines, including IL-13, cause goblet
cell metaplasia in airway epithelial cells
in vivo (25). We therefore assessed the
effects of IL-13 on expression of FOXA3
and goblet cell–related genes in primary
HBECs. Recombinant human IL-13
caused mucous metaplasia and increased
expression of FOXA3, SPDEF, and
MUC5AC in well-differentiated primary
HBECs cultured at air–liquid interface
(Figure 2A).
FOXA3 Is Sufficient to Induce Goblet
Cell Metaplasia In Vitro and In Vivo
Lentiviral-mediated expression of the
mouse Foxa3 cDNA in BEAS2B cells,
a transformed HBEC line that does not
express endogenous FOXA3, increased
expression of SPDEF, MUC5AC, MUC5B,
AGR2, and ITLN1 (Figures 2B–2D).
Because both SPDEF and AGR2 play
critical roles in the regulation of mucus
production (13, 26), we tested the effects of
Foxa3 on their transcriptional activity.
Foxa3 activated both Agr2 and Spdef gene
promoters in vitro (see Figure E1 in the
online supplement). To test whether Foxa3
was sufficient to induce goblet cell
differentiation in vivo, transgenic mice were
generated in which the mouse Foxa3 cDNA
was conditionally expressed in nonciliated
airway epithelial cells using Scgb1a1-rtTA
(line 2) (27) transgenic mice (Figure 3A).
Doxycycline induced Foxa3 and caused
marked goblet cell metaplasia (Figures 3B
and 3C). Conditional expression of Foxa3
in nonciliated secretory cells inhibited
Foxa2 in goblet cells (Figure 3B), the latter
Figure 1. FOXA3 and SPDEF in airway goblet cells from individuals with asthma and chronic obstructive pulmonary disease (COPD). FOXA3 and SPDEF
were detected by immunohistochemistry in lung tissue from the human patients with COPD and asthma. FOXA3 was present in nuclei and SPDEF
in both nuclei and cytoplasm of goblet cells in airways from patients with COPD (n = 5) and asthma (n = 3). Alcian blue staining of adjacent slides
illustrates airway mucus. FOXA3, SPDEF, and Alcian blue staining was less abundant in healthy lung tissue (n = 5) in the absence of goblet cells. Scale bar:
100 mm. Insets show higher magnification of regions indicated by arrows.
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a forkhead transcription factor family
member known to suppress goblet cell
differentiation and Th2-mediated
inflammation in the developing lung (12).
Transient expression of Foxa3 in transgenic
mice did not cause pulmonary
inflammation or alter epithelial cell
morphology in the alveoli but induced
dramatic goblet cell metaplasia in
conducting airways.
FOXA3 Is Required for SPDEF and
Mucin Gene Expression in Human
Airway Epithelial Cells
Unlike Spdef, Foxa3 was not required for
differentiation of mucous cells in
submucosal glands or in airway goblet cells
after sensitization of mice to ovalbumin (14)
(Figure E2). In contrast to these findings,
inhibition of endogenous FOXA3 by
lentiviral shRNA in primary HBECs and
Calu-3 cells, the latter a human cell line
with characteristics of submucosal gland
epithelial cells, strongly inhibited IL-
13–induced SPDEF, MUC5AC, MUC5B,
AGR2, and ITLN1 mRNAs (Figures
4A–4D). In primary HBECs, IL-13 induced
FOXA3, SPDEF, and mucus-related RNAs;
furthermore, inhibition of FOXA3 by
shRNAs blocked IL-13–induced mucus-
related RNAs (Figures 4C and 4D).
Goblet Cell Metaplasia Induced by
FOXA3 Is Not Dependent on SPDEF
Spdef is both necessary and sufficient for
airway goblet cell metaplasia in mice (13).
Because Foxa3 induced SPDEF, we used
siRNA to test whether the effects of FOXA3
on mucus production were dependent on
SPDEF. In BEAS2B cells expressing
exogenous Foxa3, expression of ITLN1 and
AGR2 persisted in spite of the inhibition of
SPDEF. Similarly, the increase in MUC5AC
induced by Foxa3 was not dependent on
SPDEF (Figures 4E and 4F).
Rhinoviral Infection Induces FOXA3
and Causes Goblet Cell Metaplasia
In Vivo and In Vitro
RVs, pathogens associated with the
common cold and clinical exacerbations in
chronic pulmonary diseases (e.g., asthma,
CF, and COPD), readily infect airway
epithelial cells causing airway inflammation
and mucus production. RV1B (a mouse-
adapted human RV, the minor group
serotype of RV) induced Spdef, Foxa3, and
Muc5ac, and goblet cell metaplasia in
conducting airways 3 days after pulmonary
Figure 2. Foxa3 induced goblet cell differentiation in vitro. (A) FOXA3, SPDEF, and MUC5ACmRNAs
were induced by IL-13 (10 ng/ml) in primary human bronchial epithelial cells during air–liquid interface
culture for 5 days. Graph is representative of n = 5 independent experiments, mean 6 SE. (B–D)
BEAS2B cells were stably transduced with a lentivirus expressing green fluorescent protein (GFP,
control) or Foxa3-IRES-GFP for 2 weeks. (B) Foxa3 increased SPDEF, AGR2, and ITLN1 in
BEAS2B cells. Glyceraldehyde 3-phosphate dehydrogenase was used as loading control for Western
blotting. (C) MUC5AC was induced by Foxa3 in BEAS2B cells shown by immunofluorescence
staining. (D) Expression of Foxa3 in BEAS2B cells increased endogenous SPDEF, MUC5AC,
MUC5B, AGR2, and ITLN1mRNAs, detected by quantitative reverse transcriptase–polymerase chain
reaction after normalization to 18S rRNA. Data are expressed as mean 6 SD of three independent
experiments, *P , 0.001 and **P , 0.05 versus controls (Student t test, two-tailed, unpaired).
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infection (Figure 5A). Likewise, exposure of
primary HBECs to RVs (both RV16,
a major group serotype, and RV1B) in vitro
increased FOXA3, SPDEF, and MUC5AC
mRNAs 48 hours after infection
(Figure 5B). Because RV infection activates
IFN to mediate antiviral innate host
defenses in airway epithelial cells, we
assessed whether IFN-b regulated FOXA3
and goblet cell–related gene expression.
IFN-b increased FOXA3, SPDEF, and
MUC5AC mRNAs in primary HBECs
24 hours after exposure (Figure 5C).
Foxa3 Inhibits RV Clearance In Vivo
Because Foxa3 is not normally widely
expressed in airway epithelial cells in the
adult mouse lung, we used HDM
sensitization to enhance Foxa3 before RV
instillation. To assess the role of Foxa3 in
viral clearance, wild-type and Foxa32/2
mice were sensitized with HDM lysates,
followed by RV1B infection. As expected,
FOXA3 was expressed in Foxa31/1 control
mice and was absent in the Foxa32/2 mice
after sensitization with HDM and exposure
to RV1B (Figure 6A). Although lack of
Foxa3 did not block expression of goblet
cell–related mRNAs (e.g., Spdef, Muc5ac,
and Muc5b) (Figure E3), Ifnb1 mRNA and
clearance of RV1B vRNA 24 hours after
infection were significantly increased in
Foxa32/2 mice (Figure 6B). To test whether
Foxa3 influenced viral clearance from the
lung, Foxa3 was induced by treatment of
Scgb1a1-rtTA, Otet7-Foxa3-IRES-EGFP
mice with doxycycline for 2 weeks before
RV1B infection. Conditional expression of
Foxa3 in airway epithelial cells significantly
inhibited RV clearance in the mouse lung
(Figure 6C).
FOXA3 Inhibits ISGs, Viral Clearance,
and Apoptosis after RV Infection
In Vitro
In BEAS2B cells, Foxa3 strongly inhibited
type I (IFNb1) and type III (IFNl1, IFNl2/
3) IFN mRNAs from 8 to 48 hours after
RV1B infection. mRNAs encoding critical
regulators of IFN responses in airway
epithelial cells, including TLR3, MDA5
(IFIH1) (16, 17), and IKK« (IKBKE) (28),
were suppressed by Foxa3. Foxa3 strongly
inhibited ISGs, including MX1, IFIT1,
Figure 3. Foxa3 caused goblet cell metaplasia in vivo. (A) Transgenic mice were produced in which Foxa3 was conditionally induced in airway epithelial
cells under control of the Scgb1a1 gene promoter. Mice were treated with doxycycline for 3 days. (A, B) Foxa3 mRNA and protein were increased.
Foxa3 caused goblet cell metaplasia as indicated by increased Alcian blue (AB), Spdef, and inhibition of Foxa2 staining. (C) Foxa3 increased Muc5ac,
Muc5b, Agr2, and Itln1 staining in airway epithelial cells. Scale bar: 100 mm. Insets show regions indicated by arrows. The graph represents mean6 SD of
five independent transgenic mice of each genotype, *P , 0.01 versus control mice (Student t test, two-tailed, unpaired).
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OAS2, ISG15, RIG-I (DDX58), and
VIPERIN (RSAD2) mRNAs (Figure 7A and
E4A). Consistent with these findings,
rhinoviral clearance was suppressed
(Figure 7A). Inhibition of IFNs and ISGs by
Foxa3 after RV1B infection was not due to
decreased expression of the RV1B receptor,
LDLR, or the IFN receptors, IFNAR1 and
IFNAR2 in BEAS2B cells (Figure E4B).
Type I IFNs induce ISG factor-3 (ISGF3),
a complex composed of activated
(phosphorylated) STAT1, STAT2, and
IRF9. Activated ISGF3 is translocated to
nucleus and binds to IFN-Stimulated
Response Elements (ISRE) present on
promoters of ISGs (29). Foxa3 inhibited
activation of ISGF3 downstream of IFN
signaling, inhibiting STAT1 and STAT2
phosphorylation, RV-induced MDA5, and
cleaved caspase-3 in BEAS2B cells
(Figure 7B). Transcription of IFNs is
regulated by phosphorylation of IFN
Regulatory Factor 3 (IRF3) (30) by IKKe
and TBK1 (28). It is likely that FOXA3
inhibits IRF-3 phosphorylation by
suppressing expression of IKKe but not
TBK1 in BEAS2B cells (Figure 7C).
Inhibition of IFN responses by Foxa3 was
demonstrated in vitro using reporter
constructs consisting of the IFN-b (pRD I/
III-luc) and ISGs promoters (pISRE-luc) in
luciferase assays. Foxa3 inhibited TRIF-
induced activation of pRD I/III-luc, pISRE-
luc promoters, and mRNAs of IFNs and
ISGs in HEK293-T cells (Figure E5) and
inhibited poly I:C and RV1B-induced IFN
production in H358 cells (Figure E6).
Inhibitory Effects of FOXA3 on
Antiviral Gene Expression and Viral
Clearance Are Reversed by IFN-b
IFN production, viral clearance, and
apoptotic responses to RV infection are
deficient in airway cells from patients
with asthma and CF (20, 22). Treatment
of Foxa3-expressing BEAS2B cells with
IFN-b restored STAT1 and STAT2
phosphorylation and expression of ISGs.
IFN-b rescued viral clearance and induced
apoptosis after RV infection in Foxa3-
expressing BEAS2B cells (Figure E7 and
E8). Inhibition of endogenous IFNb1,
IFNl1, IFNl2/3, TLR3, IKKe, and
phosphorylation of IRF3 were not reversed
by IFN-b (Figures E7A and E7C). Taken
together, inhibition of IFN production by
Foxa3 is likely mediated, at least in part, by
inhibition of IRF-3 phosphorylation and
IKKe expression.
Figure 4. Mucous metaplasia–associated gene expression was dependent on FOXA3 in human
respiratory epithelial cells. (A, B) FOXA3 was inhibited by lentiviral shRNA-mediated knockdown in Calu-3
cells resulting in suppression of SPDEF, MUC5AC, MUC5B, AGR2, and ITLN1 mRNAs and decreased
AGR2 as assessed by Western blot. FOXA3 shRNA1 was not effective. (B) Graphs are representative of
three independent experiments, means 6 SD, *P , 0.01 versus controls, Student t test, two-tailed,
unpaired; mRNA normalized to endogenous 18S rRNA. (C, D) FOXA3 shRNA2 lentivirus-mediated
knockdown inhibited endogenous FOXA3 mRNA and protein in primary human bronchial epithelial cells
(HBECs). Primary HBECs were transduced with either nontarget shRNA or FOXA3 shRNA2 lentivirus
and cultured under air–liquid interface for 10 days with puromycin (1 mg/ml). Cells were then treated with
either phosphate-buffered saline (PBS) or recombinant human IL-13 (10 ng/ml) for 5 days. Loss of
FOXA3 suppressed IL-13–induced AGR2 protein and SPDEF, ITLN1, MUC5AC, and MUC5B
mRNAs. Graphs represent means 6 SE of three independent experiments, *P , 0.05, **P , 0.01
versus controls, Student t test, two-tailed, unpaired; mRNA normalized to endogenous 18S rRNA.
(E) siRNA-mediated inhibition of endogenous SPDEF did not inhibit lenti-Foxa3–induced AGR2 or
INTL1 or MUC5AC expression as shown by immunofluorescence staining (F) in BEAS2B cells.
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mRNA and ChIP-Sequence Analysis
Identify FOXA3-regulated Genes
mRNA microarray, RNA sequence (RNA-
seq), and ChIP-Seq analysis were used to
identify potential transcriptional targets of
Foxa3. BEAS2B cells were engineered to
express mouse Foxa3 cDNA with
a lentiviral vector. A heat map of mRNAs
altered by Foxa3 is shown in Figure 8A. In
the absence of RV, Foxa3 induced the
expression of groups of genes associated
with goblet cell metaplasia, including
SPDEF, MUC5AC, MUC5B, and AGR2
mRNAs. Foxa3 suppressed genes involved
in antiviral responses, cell survival, and
programmed cell death, including TLR3,
NFKBIA (31), CASP1,4,8 (32, 33), and FAS
(34). In the presence of RV, Foxa3 inhibited
groups of genes involved in “response to
virus,” “virus RNA replication,” and “IFN
signaling” (Figure 8B). As shown in Figure
E9, network analysis supports a model by
which FOXA3 inhibits IFN signaling
through the interactions of regulatory
hubs including IRF, STAT, and nuclear
factor (NF)-kB. RNA-Seq analyses of
BEAS2B cells infected with FOXA3 showed
a high degree of correlation with
microarray data (83% overlap, r = 0.64,
Figure E10).
ChIP-Seq analyses were used to
identify potential sites by which FOXA3
regulated goblet cell and innate immune
response–related gene expression. Foxa3
lentivirus-transduced BEAS2B cells were
subjected to Foxa3 ChIP-Seq, and two
biological replicate libraries were generated.
Approximately 28 million reads were
sequenced, of which z4.1 million clustered
into regions that were enriched with
FOXA3 binding compared with genomic
background (false discovery rate , 0.01).
Irreproducible discovery rate analysis of the
two ChIP-Seq experiments identified
z14,000 replicated regions of FOXA3
occupancy (irreproducible discovery rate ,
0.1). FOXA3 occupancy was enriched at
transcriptional start sites (Wilcoxon rank
sum, P , 1 3 10211) and highly correlated
with mRNAs induced by Foxa3 in the
lentivirus-transduced cells (Figure 9A–9D).
FOXA3 ChIP-Seq peaks were enriched at
the promoters of genes activated and
repressed by FOXA3 (Wilcoxon rank sum,
P , 1 3 1026; Figures 9A–9C). To further
assess the specificity of the ChIP-Seq data,
we performed de novo motif analyses of the
Figure 5. Rhinovirus and IFN-b caused goblet cell metaplasia. (A) Foxa3 staining and goblet cell differentiation were assessed in vivo. Adult FVB/N mice
were treated with 107 pfu (100 ml of volume) of rhinovirus (RV1B), ultraviolet (UV)-irradiated RV1B, or HeLa cell conditioned medium by intratracheal
injection. Foxa3, Spdef, and Muc5ac were increased in airways 3 days after RV1B infection. Sections are representative of n = 3–5 mice in each treatment
group. Scale bar: 100 mm. (B, C) Exposure of primary human bronchial epithelial cells (HBECs) to RV16, RV1B, and IFN-b–induced FOXA3, SPDEF, and
MUC5AC mRNAs. Data are expressed as mean 6 SE of five independent experiments, *P , 0.05 and **P , 0.01 versus controls (Student t test, two-
tailed, unpaired). mRNA was normalized to endogenous 18S rRNA.
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top 500 ChIP-Seq peaks. Weeder and
Meme2 algorithms (35, 36) identified
a motif similar to the previously described
FOXA3 consensus binding site TGTTTAC,
consistent with previous findings in HepG2
cells (Figure 9E) (37). Importantly,
accumulation of this motif at FOXA3
ChIP-Seq peaks was highly significant
(Wilcoxon rank sum, P , 1 3 1026) and
highly correlated with peak rank (as
expected for a Poisson distribution)
(Figure 9F). There was no significant
enrichment for this motif at randomized
regions of the genome, including regions
offset from FOXA3 peaks, or at
transcriptional start sites that lacked
adjacent FOXA3 peaks. Moreover, FOXA3
ChIP-Seq peaks adjacent to the SPDEF,
AGR2, MUC5AC, and IKK« gene
transcriptional start sites correlated well
with the presence of predicted FOXA3
binding sites (Figures 9G, 9H, and E11).
Taken together, FOXA3 binds to and
activates SPDEF, MUC5AC, and AGR2
genes that play important roles in goblet
cell metaplasia (13, 26, 38). We also linked
FOXA3 occupancy to the repression of
genes, such as IKK« (IKBKE) and NFKBIA,
which may contribute to suppression of
innate antiviral immunity and programmed
cell death.
Foxa3 Induced TSLP and CCL-26 in
Airway Epithelial Cells
Because FOXA3 was induced by IL-13
(Figures 2A and 4), we tested whether
FOXA3 regulated factors expressed by
epithelial cells that influence Th2-mediated
immunity. Th2 cytokines and RV infection
are known to enhance TSLP and CCL-26
(eotaxin-3) expression in primary human
airway epithelial cells (39, 40). Foxa3
markedly stimulated TSLP and CCL-26
mRNAs in BEAS2B cells (Figure E10,
E12A, and E12B). CCL-26 mRNA was
further enhanced when Foxa3-expressing
BEAS2B cells were exposed to RV1B and
IL-13 (Figure E12C), supporting the
concept that expression of Foxa3 in
respiratory epithelial cells may influence
Th2-mediated inflammation. Likewise,
FOXA3 shRNA blocked IL-13 induced
CCL26 in primary HBECs in air–liquid
interface cultures (Figure E12D). Taken
together, FOXA3 induces goblet cell
differentiation, inhibits Th1 antiviral
responses, and enhances expression of
TSLP and CCL-26 that may serve to
enhance Th2 immunity.
Discussion
The present study demonstrates that
FOXA3 plays an unexpected, epithelial
cell–autonomous role integrating goblet cell
metaplasia/mucus production and
suppression of antiviral innate immunity.
FOXA3 was sufficient to induce goblet cell
metaplasia in vivo and in vitro. We propose
a model that supports a counterregulatory
role for FOXA3 in suppressing ongoing
inflammation, perhaps mediating
resolution of acute infections in the normal
airway. In turn, persistent expression of
FOXA3 and accompanying goblet cell
metaplasia may inhibit antiviral responses
that may render individuals with chronic
pulmonary disorders susceptible to
recurrent pulmonary infection.
In both in vitro and in vivo studies, we
found that FOXA3 was sufficient to cause
goblet cell metaplasia in airway epithelial
cells. Because FOXA3 bound to and
induced SPDEF, a gene required for goblet
cell differentiation in the airway epithelium,
the observed effects of FOXA3 on mucus-
related gene expression are likely mediated,
at least in part, by its ability to induce
SPDEF. However, FOXA3 directly bound
to and induced AGR2 and MUC5AC that
are critical for mucus production/goblet cell
metaplasia in the airways (1, 26, 38),
functioning independently of SPDEF to
regulate these genes in human airway
epithelial cells (Figures 4, 9, and E11).
Present findings that FOXA3 mediated
goblet cell–associated genes in human
respiratory epithelial cells, including
HBECs, Calu3 cells, and BEAS2B cells, may
contrast with findings in the allergen-
exposed mouse models wherein Spdef, but
not Foxa3, was required for goblet cell
metaplasia (13, 14), differences that may be
related to epithelial cell types, species
Figure 6. Foxa3 inhibited rhinovirus clearance in vivo. Wild-type (WT) and Foxa32/2 mice were
sensitized with house dust mite (HDM) extract to induce endogenous Foxa3 in the airway epithelium
before rhinovirus (RV1B) infection. (A) Nuclear staining of Foxa3 was detected in the airway epithelium
of HDM- and RV1B-sensitized WT mice (n = 3) and was absent in Foxa32/2 mice (n = 3). Scale bar:
100 mm. (B, C) RV1B viral RNA (vRNA) was assessed in lung homogenates from Foxa32/2 and
Scgb1a1/Foxa3-expressing mice after viral infection. Increased viral clearance, indicated by
decreased RV1B vRNA remaining, and increased Ifnb mRNA in the lung were observed in the
Foxa32/2 mice (n = 8) compared with WT mice (n = 8) (B). (C) Conditional expression of Foxa3 in the
airway epithelium impaired viral clearance from the lung. Foxa3 was induced in the airway epithelium
of Scgb1a1-rtTA/Otet7-Foxa3-IRES-EGFP (Scgb1a1/Foxa3) transgenic mice by treatment with
doxycycline for 2 weeks before RV1B exposure. Viral clearance was decreased in mice expressing
Foxa3 (Scgb1a1/Foxa3, n = 14) compared with control mice (Scgb1a1, n = 12). Data were
presented as means 6 SE, analyzed by a two-tailed, unpaired, nonparametric Mann-Whitney t test.
vRNA and mRNA were normalized to endogenous 18S rRNA.
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differences, and the nature and duration of
inducing stimuli in vivo and in vitro.
Mucous metaplasia associated with
chronic lung diseases is often accompanied
by increased sensitivity to respiratory viral
infection. Bronchial epithelial cells from
patients with asthma lack normal IFN
responses to RV and fail to clear the virus
normally (20). The relationship between
virus, FOXA3, and IFN response are
complex and are likely dose dependent. For
example, IFN-a/b has paradoxical effects
on hepatitis B virus replication. IFN-a/b
enhanced viral replication, Foxa3, and
activating STAT3, which together
stimulated hepatitis B virus gene expression
and replication (41, 42). In the current
study, we found that FOXA3 was induced
by both RV and IFN-b and strongly
suppressed IFN production and an entire
network of genes regulated by IFNs in
airway epithelial cells, including those
critical for viral recognition and viral
replication. FOXA3 inhibited STAT-2,
TLR3, IRF-1, IRF-7, and IRF-9 mRNAs,
supporting its broad role in the regulation
of ISGs. Because IRF-3 phosphorylation
by IKKe is known to be a critical
transcriptional regulator of IFN production
(28), the finding that FOXA3 inhibited
RV-induced IKKe, and directly bound to
the IKK« gene promoter in ChIP-Seq
experiments (Figures E11B and E11D) is
consistent with a direct transcriptional role
for FOXA3 in the inhibition of IFN
pathways that is mediated, at least in part,
via its inhibitory effects on IRF-3
phosphorylation. Some of the
antiinflammatory effects of FOXA3 may be
influenced by its ability to enhance SPDEF,
the latter recently shown to inhibit NF-kB
by binding to and inhibiting the adaptor
proteins MyD88 and TRIF in the cell
cytoplasm (23). Thus, as observed in the
regulation of mucus-associated gene
expression, FOXA3 and SPDEF may serve
both overlapping and complementary roles
in the regulation of innate immunity and
viral host defenses in airway epithelial cells.
Paradoxically, although RV and IFN initiate
strong antiviral innate immune responses
in respiratory epithelial cells, we speculate
that the induction of Foxa3 may serve
a counterregulatory role that may be useful
in dampening inflammation during the
recovery from acute infections but may
inhibit antiviral responses in the setting of
Figure 7. FOXA3 inhibited IFNs, IFN-stimulated genes, and viral replication in vitro. BEAS2B cells expressing lenti-GFP or lenti-Foxa3 were exposed to
rhinovirus (RV1B) (multiplicity of infection of 2) for 30 minutes to 48 hours (panels A–C). (A) Foxa3 inhibited IFNb1, IFNl1, IFNl2/3, TLR3, MDA5, MX1, IFIT1,
and IKK« mRNAs. RV1B viral RNA (vRNA) was increased by Foxa3, indicating inhibition of viral clearance at 48 hours. vRNA and mRNA were normalized to
endogenous 18S rRNA. Data represent means 6 SD of three independent experiments, *P , 0.001, **P , 0.05 versus control, Student t test, two-tailed,
unpaired. (B) Western blot analysis demonstrated that Foxa3 inhibited STAT1, STAT2 phosphorylation, and MDA5. Foxa3 inhibited RV1B-induced apoptosis
shown by decreased cleaved-caspase 3. (C) Western blot demonstrated that IKKe and phosphorylation of IRF3 were inhibited by Foxa3. TBK1 expression
was induced in the presence of Foxa3 at 30 minutes, and only slightly increased by Foxa3 24 hours and 48 hours after RV infection. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used as loading control for Western Blotting. GFP = green fluorescent protein; MW = molecular weight.
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chronic mucous metaplasia. The present
findings are consistent with recent studies
wherein IFN was required for normal viral
clearance during acute infection but
suppressed viral responses in the setting of
chronic infection (43, 44).
Treatment with IFN enhanced RV
clearance and restored apoptotic responses
in airway epithelial cells derived from
patients with asthma and CF in which these
responses were impaired (20–22, 45, 46).
We presently observed that Foxa3 inhibited
RV-induced caspase-3 cleavage, as well as
caspase-1 and caspase-4 mRNAs, inhibition
of caspase-3 cleavage being reversed by
treatment with IFN-b. The inhibitory
effects of Foxa3 on apoptotic pathways in
airway epithelial cells may contribute to its
inhibitory effects on RV clearance, findings
consistent with previous studies that
associated goblet cell metaplasia with poor
apoptotic response (47, 48) and increased
susceptibility to RV infection (49).
Respiratory epithelial cells produce
cytokines and chemokines that serve as
proximal events in initiating and amplifying
inflammatory and immune responses in bone
marrow–derived cells (e.g., dendritic cells,
macrophages, neutrophils, lymphocytes,
eosinophils, and mast cells) (50). Previous
studies indicate that the TSLP, the epithelial
cell–derived cytokine that activates maturation
of dendritic cells, is induced by NF-kB (51)
and by RV (39), the latter in a process
mediated by IRF-3 (52). In the present study,
we demonstrated that FOXA3 induced
expression of TSLP and CCL26, providing
a potential mechanism linking goblet cell
metaplasia to the expression of Th2 polarizing
mediators by the respiratory epithelium.
The present studies identify a novel role
of FOXA3 in the regulation of goblet cell
differentiation and suppression of antiviral
responses in airway epithelial cells. FOXA3
plays a role in a transcriptional network with
SPDEF that induces goblet cell metaplasia
and modulates Th1 and Th2 innate immune
responses. The current study defines a novel
molecular mechanism that may contribute
to mucus production, impairment of IFN
responses, and deficient viral host defenses
characteristic of individuals with asthma,
COPD, and CF. n
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Figure 8. FOXA3 induced mucus-related gene expression and suppressed genes involved in response to virus. (A) mRNAs were isolated from lentiviral
Foxa3-expressing and control BEAS2B cells and subjected to mRNA microarray analysis. A heat map of mRNAs altered by Foxa3 in presence or absence
of rhinovirus (RV1B) is shown. Green and red denote mRNAs decreased and increased, respectively, by Foxa3 with or without RV1B infection. (B) Type I
interferon-mediated signaling pathway (green fluorescent protein [GFP]-RV1B vs. GFP) was the most suppressed bioprocess when comparing Foxa3-RV1B
versus GFP-RV1B. A list of mRNAs involved in type I IFN-mediated signaling pathway influenced by Foxa3 in the presence of virus is shown.
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Figure 9. Chromatin immunoprecipitation sequencing (ChIP-Seq) and RNA sequencing (RNA-Seq) identify transcriptional targets of FOXA3 involved in goblet
cell metaplasia. ChIP-Seq was performed on BEAS2B cells after infection with lenti-Foxa3 or control lentivirus as described in the online supplement. (A, B)
UCSC Genome browser tracks depict FOXA3 ChIP-Seq peaks and irreproducible discovery rate (IDR)-selected peaks (IDR is analogous to the false
discovery rate) from two separate experiments (b1 and b2) demonstrating FOXA3 binding to the promoter and first intronic region of the SPDEF and AGR2
genes. The ChIP-Seq peaks are shown at the top three tracks of the figure. RNA-Seq reads density are shown at the bottom two tracks of the figure. (C)
Heat maps depict BEAS2B ChIP-Seq sequence density (500-bp bins) of all RefSeq genes rank-ordered by levels of gene expression from RNA-Seq
data that show the correlation of H3K4me3 (activation mark) with the density of FOXA3 binding sites in two independent experiments (b1 and b2). The color
ramp shows maximum–minimum–scaled expression as follows: green . red . blue. white. Regions 5 kb up- and downstream of transcriptional start sites
(TSS) are depicted with the TSS located in the middle. Regions surrounding TSS displayed highest ChIP-Seq tag density as well as highest level of gene
expression. Expression levels were determined by sorting RNA-Seq data by normalized tag counts annotated to RefSeq gene exons. All RefSeq gene lengths
were scaled to 1. (D) Pie chart depicts the genomic annotation of FOXA3 binding sites with respect to known RefSeq genes in UCSC genome browser.
Percentage distribution of FOXA3 binding sites are shown by color: promoter, red; 39, intergenic, green; intragenic, yellow. (E) De novo motif algorithm
identifies the FOXA3 consensus motif overrepresented in the FOXA3 ChIP-Seq peak regions. (F) An accumulation plot depicts the percentage of FOXA3
consensus binding motif relative to all FOXA3 IDR-selected ChIP-Seq peaks. Offset denotes a region 2 kb upstream of the ChIP-Seq locus used to assess
nonspecific binding. Random indicates randomized motif positions. “Promoter” indicates gene start sites without adjacent ChIP-Seq peaks. (G, H) UCSC
genome browser tracks highlight FOXA3 motifs relative to the promoter-proximal SPDEF and AGR2 ChIP-Seq peaks.
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